- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05437393
Children's Adaptive Deep Brain Stimulation for Epilepsy Trial (CADET): Pilot (CADET Pilot)
The CADET Pilot will investigate the safety and feasibility of deep brain stimulation (DBS) to treat children with Lennox-Gastaut syndrome using a novel DBS device (Picostim DyNeuMo-1).
Following a 30-day preoperative/baseline assessment phase, all children will have a neurosurgical procedure to implant the device. Implantation will be followed by a 30-day phase of no stimulation (the device is off / inactive) and then a six-month phase of active stimulation (the device is on / active).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The CADET pilot will be a single-arm, multi-site, interventional clinical trial. This design has been chosen since this is a feasibility and safety trial in a small number of patients and thus does not primarily aim to determine efficacy.
In this pilot clinical trial, four children with drug-resistant LGS will undergo bilateral CMN DBS.
Following the DBS insertion, all children will undergo one month of inactive ('off') DBS in order to allow the lesioning effect of electrode implantation to dissipate. Thereafter, children will receive active ('on') DBS therapy with standard stimulation parameters for six-months. Following the 'on' phase of the trial, the child will then transition into continuing clinical care and will have their stimulation parameters altered according to clinical evaluation.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rory J Piper, MRCS
- Phone Number: 20 7405 9200
- Email: rory.piper.20@ucl.ac.uk
Study Contact Backup
- Name: Martin M Tisdall, FRCS
- Phone Number: 20 7405 9200
- Email: m.tisdall@ucl.ac.uk
Study Locations
-
-
-
London, United Kingdom
- Not yet recruiting
- King's College Hospital NHS Foundation Trust
-
Contact:
- Antonio Valentin, PhD
-
London, United Kingdom
- Recruiting
- Great Ormond Street Hospital NHS Foundation Trust
-
Contact:
- Rory Piper, MRCS
-
Contact:
- Martin Tisdall, FRCS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
INCLUSION CRITERIA:
Children enrolled in this study must:
- Be 5-14 years of age at consent.
Have a diagnosis of Lennox-Gastaut Syndrome, as determined by:
- Slow (<3.0Hz) spike-and-wave pattern and/or fast wave pattern (tonic seizures) on EEG for at least six-months months prior to the enrolment into the baseline period
- History of drop seizures (tonic, atonic, or tonic-clonic) for at least six-months prior to the enrolment into the baseline period
- Experience at least 10 seizures per month.
- Have tried and not responded to two or more antiseizure medications prior to enrolment.
- Be taking one or more anti-seizure medication(s) at a stable dose for at least the four weeks prior and have a parent/guardian(s) who is willing for their child's maintenance anti-seizure drugs to be unaltered for the trial duration.
- If on a ketogenic diet, have been established on a stable ketogenic diet for at least 12 weeks prior to screening and the parent/guardian(s) to be willing for child to stay on a stable ketogenic for the duration of the trial.
Have a parent/guardian(s) who is willing and able to comply with all the requirements of the study, including the completion of the seizure diary and periodic device charging.
-------------------------------
EXCLUSION CRITERIA:
Children enrolled in this study must not:
- Have had prior deep brain stimulation insertion.
- Have an active ('on') vagus nerve stimulator (or active within the six months prior to the baseline period).
- Have abnormal thalamic anatomy detected on imaging that would render DBS either unsafe or unfeasible.
- Have a bleeding disorder.
- Have medical conditions/factors that would increase their anaesthetic risk to an unacceptable level.
- Have a nickel allergy
- Be pregnant
- Participate in contact sports
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Deep brain stimulation
Deep Brain stimulation using a novel device: Bioinduction "Picostim" Deep Brain Stimulation system.
|
Deep brain stimulation of the centromedian nucleus (bilateral)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse evens
Time Frame: Following 6-months of active stimulation
|
Measured according to pre-determined device-related AEs and SAEs, as well as generic AEs and SAEs.
|
Following 6-months of active stimulation
|
Willingness of the participants/parents/guardians for the participant to be recruited into the study and to undergo the intervention
Time Frame: Following 6-months of active stimulation
|
Consent at baseline
|
Following 6-months of active stimulation
|
Participant completion of the study
Time Frame: Following 6-months of active stimulation
|
Completion of all study activities at study exit
|
Following 6-months of active stimulation
|
Ability of the participant/parent(s)/guardian(s) to re-charge and maintain the device
Time Frame: Following 6-months of active stimulation
|
Device recharging is measured using the Picostim event logs
|
Following 6-months of active stimulation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative change in parent-reported seizure frequency
Time Frame: Following 6-months of active stimulation (compared to baseline)
|
Measured using parent-reported diaries
|
Following 6-months of active stimulation (compared to baseline)
|
Relative change in electrographic-recorded seizure frequency
Time Frame: Following 6-months of active stimulation (compared to baseline)
|
Measured using serial electroencephalography (EEG)
|
Following 6-months of active stimulation (compared to baseline)
|
Relative change in seizure severity
Time Frame: Following 6-months of active stimulation (compared to baseline)
|
Measured using the Hague Seizure Severity Scoring questionnaire.
Minimum score = 13; maximum score = 52; with higher seizure severity with ascending values.
|
Following 6-months of active stimulation (compared to baseline)
|
Relative change in quality of life
Time Frame: Following 6-months of active stimulation (compared to baseline)
|
Measured on the Pediatric Quality of Life Inventory (PedsQL) questionnaire.
The minimum score is 0 and the maximum score is 100, with improving quality of life with ascending values.
|
Following 6-months of active stimulation (compared to baseline)
|
Relative change in quality of life
Time Frame: Following 6-months of active stimulation (compared to baseline)
|
Measured on the Impact of Pediatric Epilepsy Scale (IPES) questionnaires.
The minimum score is 0 and the maximum score is 100, with improving quality of life with ascending values.
|
Following 6-months of active stimulation (compared to baseline)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiological correlates of neurophysiological and clinical response to CMN DBS
Time Frame: Following 6-months of active stimulation
|
Analysis of pre-trial MRI brain scan in conjunction with relative change in seizure counts measured using parent-reported diaries
|
Following 6-months of active stimulation
|
Correlates of the scalp EEG with the intracranial recordings (local field potentials) from the DBS device.
Time Frame: Following 6-months of active stimulation
|
Analysis of local-field potentials measured from the DBS device in conjunction with data from the encephalography (EEG) data
|
Following 6-months of active stimulation
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 141267
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on Deep brain stimulation
-
Abbott Medical DevicesTerminatedDepressive Disorder, Major | Unipolar DepressionUnited States, Canada, United Kingdom
-
Zhiqi MaoRecruitingParkinson's Disease | Executive Function | Electroencephalogram | Functional Near - Infrared SpectroscopyChina
-
Ali Rezai, MDCompleted
-
University Hospital Inselspital, BerneCompletedMovement Disorder | Urinary Tract DiseaseSwitzerland
-
University of MinnesotaRecruitingParkinson DiseaseUnited States
-
NewronikaTerminatedParkinson DiseaseItaly
-
Butler HospitalMedtronicCompletedObsessive-Compulsive DisorderUnited States
-
Qilu Hospital of Shandong UniversityRecruiting
-
University of Sao Paulo General HospitalUnknownCerebellar AtaxiaBrazil
-
Boston Scientific CorporationCompletedParkinson's DiseaseUnited States